Trial · NCT06973902
The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
NCT06973902, Recruiting, Quovadis Associazione
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF. Trials, record NCT06973902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06973902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Predictive Value of Dobutamine Echo-stress in the Clinical Response to CCM Therapy in Advanced HF
- NCT number
- NCT06973902
- Status
- Recruiting
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Quovadis Associazione
- Conditions
- Symptomatic Congestive Heart Failure
- Interventions
- Cardiac Contractility Modulation (CCM) implant
- First posted
- 2025-05-15
- Last updated
- 2025-07-29
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | New York Heart Association class variation | From enrollment to the end of follow-up, 12 months | The proportion of subjects with clinical response to CCM therapy at 12 months, defined as a reduction of at least 1 class of the New York Heart Association Classification of the functional status of the heart (minimum value I, better outcome, and maximum value IV, worse outcome) |
| Secondary | Hospitalizations | From enrollment to the end of follow-up, 12 months | Change in the number of hospitalizations, visits to the Emergency Department, or access to day hospital facilities for more than 4 hours (e.g., by intravenous infusion of cardiac inotropic drugs) compared to the year before the study. |
| Secondary | Minnesota LIVING WITH HEART FAILURE Questionnaire score variation | From enrollment to the end of follow-up, 12 months | Change in the quality-of-life score estimated with the "Minnesota LIVING WITH HEART FAILURE Questionnaire" MLHFQ (minimum value 0, better outcome, and maximum value 105, worse outcome), |
| Secondary | 6MWT variation | From enrollment to the end of follow-up, 12 months | Change in walk distance between baseline and end of follow-up in the walk test (6MWT) |
| Secondary | NT-proBNP variation | From enrollment to the end of follow-up, 12 months | Change in NT-proBNP level between baseline and end of follow-up |
| Secondary | LVESV change | From enrollment to the end of follow-up, 12 months | The proportion of subjects with LVESV decreased by ≥ 15% on echocardiography at end-of-follow-up compared to preimplantation |
| Secondary | VTI change | From enrollment to the end of follow-up, 12 months | The proportion of subjects with increased integral velocity time (VTI) ≥ 20% between preimplantation and end-of-follow-up echocardiography, |
| Secondary | LVEF change | From enrollment to the end of follow-up, 12 months | The proportion of subjects with a 20% increase in ejection fraction (LVEF) between preimplantation and end-of-follow-up echocardiography |
| Secondary | MR change | From enrollment to the end of follow-up, 12 months | The proportion of subjects with progression or, conversely, improvement in Mitral Regurgitation (M.R.; classified as mild, moderate, or severe). |
| Secondary | CRT implant | From enrollment to the end of follow-up, 12 months | The proportion of subjects who, during follow-up, will be evolved to cardiac resynchronization system (CRT) implantation |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers16
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06973902
GET https://conductscience.org/api/trials/v1/NCT06973902/registered